Koers Isodiol International Inc. Canadian Securities Exchange
Aandelen
ISOL
CA46500L2003
Farmaceutische producten
Omzet 2018 | 19,14 mln. 26,36 mln. 17,98 mln. | Omzet 2019 | 22,25 mln. 30,64 mln. 20,9 mln. | Marktkapitalisatie | 49,96 mln. 68,81 mln. 46,94 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2018 | -36 mln. -49,58 mln. -33,83 mln. | Nettowinst (verlies) 2019 | -126 mln. -174 mln. -118 mln. | EV/omzet 2018 | 12,6 x |
Nettoliquiditeiten 2018 | 15,55 mln. 21,42 mln. 14,61 mln. | Nettoschuld 2019 | 5,22 mln. 7,19 mln. 4,91 mln. | EV/omzet 2019 | 2,48 x |
K/w-verhouding 2018 |
-4,94
x | K/w-verhouding 2019 |
-0,37
x | Werknemers | - |
Dividendrendement 2018 * |
-
| Dividendrendement 2019 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24-05-17 |
Director/Board Member | - | 30-08-18 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14-02-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24-05-17 |
Director/Board Member | - | 30-08-18 | |
Director/Board Member | - | 21-11-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,29% | 6,02 mld. | |
-15,73% | 4,55 mld. | |
-9,40% | 3,13 mld. | |
-1,60% | 3,07 mld. | |
-1,23% | 2,57 mld. | |
+34,89% | 1,82 mld. | |
-11,37% | 1,63 mld. | |
-5,02% | 1,57 mld. | |
-13,21% | 1,54 mld. |